Pentapeptide Plnpk Ameliorates Adjuvant Arthritis And Inhibits T Cell Activation By Suppressing Lck And Pi3k Activities

Jia Sun,Song Wang,Yong-Ci Zhang,Zheng Fu,Zhi-Feng Zhu,Jing Jia,Qiong Xu,Li Wang,Jin-Ping Li,Rong Lu,Zhi Yao

2017-01-01

Abstract:The pentapeptide PLNPK could inhibit the transformation and proliferation of mouse T lymphocytes in mice. Rheumatoid arthritis (RA) is essentially a kind of T cell-mediated arthritis. Therefore, we assessed the therapeutic ability of PLNPK on adjuvant arthritis (AA) rats, and examined its effects on signals of CD4(+) T cell activation. Isolated CD4(+) T cells were stained with CFSE, and stimulated by anti-CD3 or anti-CD3 and anti-CD28 monoclonal antibodies. The suppression effects of PLNPK on T cell proliferation and CD25 expression were detected by flow cytometry. AA rats received PLNPK or saline intraperitoneal injection once a day for 20 days. Effects on disease progression were assessed by measurement of paw swelling. Inflammation and joint destruction were examined by histology, T cell infiltration and activation in joint were detected by immunohistochemistry stain. The suppression effects of PLNPK on Lck and PI3K ability in CD4(+) T cells and in AA rats were assessed by immunoprecipitation and kinase assay kits. PLNPK inhibited the CD4(+) T cell proliferation and altered their CD25 expression when they received CD3 mAb or CD3/CD28 mAbs stimulation. In AA rats, PLNPK inhibited T cell infiltration and activation in joint. In addition, PLNPK inhibited Lck activity in CD3 mAb stimulated CD4(+) T cells as well as PI3K activity in CD3/CD28 mAbs stimulated CD4(+) T cells In vivo. PLNPK can also reduce the Lck and PI3K activities in AA rat splenocytes. PLNPK exerts its immunosuppressive effects and ameliorates adjuvant arthritis by inhibiting the Lck and PI3K activities in T cells.